Sobi rises on strong 3rd-qtr 2023 revenue and solid performance

30 October 2023

Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, saw its shares rise 5.5% to 235.80 Swedish kronor in early trading today, as it released financial results for the third quarter of 2023.

Sobi said that revenue increased 29%, +23% at constant exchange rates (CER), to 5,168 million Swedish kronor ($464.3 million).

Adjusted earnings before interest, taxes, and amortization (EBITA) margin was 30%, excluding items affecting comparability (IAC). EBITA was 1,443 million kronor, corresponding to a margin of 28%. EBIT was 547 million kronor.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK